Drugmakers Think Blockchains Could Improve Clinical Trials
Three big pharmaceutical firms—Pfizer, Amgen, and Sanofi—are working together to use blockchains to speed up clinical tests of new drugs, according to CoinDesk.
The problem: Patient data that’s crucial to locating individuals for clinical trials is usually scattered across multiple proprietary systems that are often incompatible with each other. That can make it hard to recruit for trials.
How blockchains could help: A distributed ledger could allow individual patients to store data anonymously and make it visible to trial recruiters, who could then reach out to individuals who meet the eligibility criteria for a given trial. It could also streamline communication between doctors and patients during the trial.
It’s still early: Technologists are still mostly experimenting with blockchain-based medical records systems, and big technical challenges remain. The health-care industry is also heavily regulated and tends to be risk averse, which could impede adoption.
Keep Reading
Most Popular
This startup wants to copy you into an embryo for organ harvesting
With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.
VR is as good as psychedelics at helping people reach transcendence
On key metrics, a VR experience elicited a response indistinguishable from subjects who took medium doses of LSD or magic mushrooms.
This artist is dominating AI-generated art. And he’s not happy about it.
Greg Rutkowski is a more popular prompt than Picasso.
This nanoparticle could be the key to a universal covid vaccine
Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.